Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
$10.89
-2.1%
$11.87
$8.08
$18.23
$380.93M0.82583,446 shs694,655 shs
Penumbra, Inc. stock logo
PEN
Penumbra
$265.19
+0.2%
$246.20
$184.80
$310.00
$10.34B0.4494,914 shs599,164 shs
RxSight, Inc. stock logo
RXST
RxSight
$8.61
-7.2%
$9.72
$6.32
$58.23
$352.32M1.161.04 million shs1.07 million shs
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
$42.66
-5.2%
$35.72
$5.21
$46.58
$365.60M1.2952,091 shs38,182 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
0.00%+7.34%-2.54%-30.97%+38.83%
Penumbra, Inc. stock logo
PEN
Penumbra
0.00%+4.62%+13.51%-1.51%+25.96%
RxSight, Inc. stock logo
RXST
RxSight
0.00%+10.08%+16.44%-40.82%-83.56%
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
0.00%+16.55%+18.86%+57.62%+4,499,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
2.7639 of 5 stars
3.52.00.00.02.62.50.6
Penumbra, Inc. stock logo
PEN
Penumbra
4.7557 of 5 stars
3.55.00.03.72.32.51.9
RxSight, Inc. stock logo
RXST
RxSight
1.6275 of 5 stars
3.01.00.00.02.31.70.6
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
2.5418 of 5 stars
3.50.00.00.03.32.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
3.00
Buy$24.50124.98% Upside
Penumbra, Inc. stock logo
PEN
Penumbra
2.94
Moderate Buy$300.4713.30% Upside
RxSight, Inc. stock logo
RXST
RxSight
1.91
Reduce$10.0016.14% Upside
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
3.00
Buy$55.0028.93% Upside

Current Analyst Ratings Breakdown

Latest PEN, SNWV, DCTH, and RXST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/22/2025
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$54.00 ➝ $55.00
8/8/2025
RxSight, Inc. stock logo
RXST
RxSight
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$16.00 ➝ $8.00
8/8/2025
RxSight, Inc. stock logo
RXST
RxSight
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$9.00 ➝ $8.00
8/8/2025
RxSight, Inc. stock logo
RXST
RxSight
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$22.00 ➝ $11.00
8/7/2025
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$29.00 ➝ $31.00
7/31/2025
Penumbra, Inc. stock logo
PEN
Penumbra
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$260.00 ➝ $266.00
7/30/2025
Penumbra, Inc. stock logo
PEN
Penumbra
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$300.00 ➝ $310.00
7/30/2025
Penumbra, Inc. stock logo
PEN
Penumbra
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$330.00 ➝ $325.00
7/30/2025
Penumbra, Inc. stock logo
PEN
Penumbra
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$330.00 ➝ $335.00
7/30/2025
Penumbra, Inc. stock logo
PEN
Penumbra
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$315.00 ➝ $290.00
7/30/2025
Penumbra, Inc. stock logo
PEN
Penumbra
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$283.00 ➝ $285.00
(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
$37.21M10.24N/AN/A$2.15 per share5.07
Penumbra, Inc. stock logo
PEN
Penumbra
$1.19B8.66$2.89 per share91.71$29.99 per share8.84
RxSight, Inc. stock logo
RXST
RxSight
$139.93M2.52N/AN/A$6.98 per share1.23
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
$32.63M11.20N/AN/A($1.49) per share-28.63
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
-$26.39M$0.05217.80N/AN/A3.18%6.91%5.80%N/A
Penumbra, Inc. stock logo
PEN
Penumbra
$14.01M$3.7670.5352.932.3811.54%11.55%8.76%10/29/2025 (Estimated)
RxSight, Inc. stock logo
RXST
RxSight
-$27.45M-$0.80N/AN/AN/A-21.93%-11.56%-10.31%11/6/2025 (Estimated)
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
-$31.37M-$8.25N/AN/A-97.03%N/A-135.15%N/A

Latest PEN, SNWV, DCTH, and RXST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/8/2025Q2 2025
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
-$0.09$0.01+$0.10$0.01$10.14 million$10.16 million
8/7/2025Guidance Update
RxSight, Inc. stock logo
RXST
RxSight
-$0.04-$0.08-$0.04-$0.29$39.78 million$33.64 million
8/6/2025Q2 2025
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
$0.02$0.07+$0.05$0.07$22.84 million$24.16 million
7/29/2025Q2 2025
Penumbra, Inc. stock logo
PEN
Penumbra
$0.81$0.86+$0.05$1.15$327.37 million$339.46 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
N/AN/AN/AN/AN/A
Penumbra, Inc. stock logo
PEN
Penumbra
N/AN/AN/AN/AN/A
RxSight, Inc. stock logo
RXST
RxSight
N/AN/AN/AN/AN/A
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
N/A
10.88
9.87
Penumbra, Inc. stock logo
PEN
Penumbra
0.02
6.75
4.04
RxSight, Inc. stock logo
RXST
RxSight
N/A
13.93
12.70
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
N/A
0.43
0.31

Institutional Ownership

CompanyInstitutional Ownership
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
61.12%
Penumbra, Inc. stock logo
PEN
Penumbra
88.88%
RxSight, Inc. stock logo
RXST
RxSight
78.78%
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
42.53%

Insider Ownership

CompanyInsider Ownership
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
17.94%
Penumbra, Inc. stock logo
PEN
Penumbra
5.00%
RxSight, Inc. stock logo
RXST
RxSight
9.57%
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
14.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
6034.98 million28.71 millionOptionable
Penumbra, Inc. stock logo
PEN
Penumbra
4,50039.00 million37.05 millionOptionable
RxSight, Inc. stock logo
RXST
RxSight
22040.92 million37.00 millionOptionable
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
408.57 million7.29 millionN/A

Recent News About These Companies

Roth Capital Increases Sanuwave Health (NASDAQ:SNWV) Price Target to $55.00
Sanuwave (SNWV) Q2 Revenue Jumps 42%
Sanuwave Announces Q2 FY2025 Financial Results
SANUWAVE Health, Inc. (SNWV): A Bull Case Theory
Sanuwave Announces Q1 FY2025 Financial Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Delcath Systems stock logo

Delcath Systems NASDAQ:DCTH

$10.89 -0.23 (-2.07%)
Closing price 04:00 PM Eastern
Extended Trading
$11.35 +0.46 (+4.25%)
As of 05:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Penumbra stock logo

Penumbra NYSE:PEN

$265.19 +0.45 (+0.17%)
Closing price 03:59 PM Eastern
Extended Trading
$264.17 -1.02 (-0.39%)
As of 05:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

RxSight stock logo

RxSight NASDAQ:RXST

$8.61 -0.67 (-7.22%)
Closing price 04:00 PM Eastern
Extended Trading
$8.82 +0.21 (+2.38%)
As of 05:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Sanuwave Health stock logo

Sanuwave Health NASDAQ:SNWV

$42.66 -2.34 (-5.20%)
As of 04:00 PM Eastern

SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.